Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis

Mohamed Kamal, Matthew P. Kosloski, Ching‐Ha Lai, Michael A. Partridge, Manoj Rajadhyaksha, Vanaja Kanamaluru, Ashish Bansal, Arsalan Shabbir, Brad Shumel, Marius Ardeleanu, Susan Richards, Hong Yan, Christine Xu, Ainara Rodríguez-Marco, Jing Xiao, Faisal A. Khokhar, Guy Gherardi, Elisa Babilonia, Jennifer Maloney, Eric Mortensen, Bolanle Akinlade, Ned Braunstein, Neil Stahl, Albert Torri, John D. Davis, A. Thomas DiCioccioFrontiers in Immunology 2024 · DOI

Abstract

This study presents a large-scale pooled analysis of over 5,000 patients from the LIBERTY AD clinical program, including trials NCT02277743, NCT02277769, NCT02260986, NCT02395133, NCT01949311, NCT03054428, NCT03345914, NCT02612454, and NCT03346434. The analysis demonstrates that dupilumab maintains a low immunogenicity profile across the entire age spectrum, from infants (6 months) to adults. While anti-drug antibodies (ADAs) occur in a minority of patients, they are typically low-titer and transient; only rare high-titer responses significantly impact drug concentration or clinical efficacy.

Introduction

Monoclonal antibodies (mAbs) such as dupilumab—which targets the IL-4Rα receptor to treat atopic dermatitis (AD)—are complex proteins that the human immune system may recognize as foreign. This recognition can lead to the development of anti-drug antibodies (ADAs), including neutralizing antibodies (NAbs) that block the drug's active site. The primary clinical concern is that these immune responses might lead to a secondary loss of efficacy or safety issues, such as allergic reactions. While individual trials have assessed these risks, this paper provides the first comprehensive, longitudinal analysis of immunogenicity across all approved age groups using data from nine clinical trials.

Methods

The researchers conducted a pooled analysis of seven Phase 3 randomized controlled trials (RCTs) and two long-term open-label extension (OLE) studies.

  • Detection and Quantification: Validated electrochemiluminescence (ECL) bridging immunoassays were used to detect ADAs, while competitive ligand-binding assays identified NAbs. ADA responses were categorized by titer: low (<1,000), moderate (1,000–10,000), and high (>10,000).
  • Impact Assessment: The study correlated ADA status and titer levels with serum drug concentrations, safety events, and clinical efficacy, primarily measured via the Eczema Area and Severity Index (EASI).
  • Patient Population: The dataset included 2,992 patients from RCTs (SOLO 1 & 2, CHRONOS, SOLO-CONTINUE, ADOL, PEDS, and PRESCHOOL) and 2,287 patients from long-term OLEs, totaling over 5,000 participants.

Key Results

The analysis revealed that the incidence of treatment-emergent ADAs varies by age group but remains relatively low overall. Notably, a peak in ADA frequency was observed in adolescents compared to other age groups.

Incidence of treatment-emergent anti-drug antibodies (ADAs) across age groups in Phase 3 and long-term OLE trials.

Specific findings include:

  • Incidence Rates: Treatment-emergent ADAs were observed in 8.6% of adults, 16.0% of adolescents, 5.3% of children, and 2.0% of infants in Phase 3 trials. Long-term OLE data showed a similar trend with slightly lower percentages.
  • Titer Significance: The presence of ADAs was less clinically relevant than the titer level. High-titer responses (≥10,000) were extremely rare, occurring in less than 1% of all treated patients. These high-titer responses were the primary drivers of reduced drug levels and diminished clinical response.
  • Persistence and Tolerance: Most ADA responses were transient or indeterminate. Persistent responses (detected over 12+ weeks) occurred in fewer than 4% of patients. Interestingly, in many patients with moderate-to-high titers, antibody levels decreased over time with continued treatment, suggesting the development of immune tolerance.
  • Safety and Efficacy: For the vast majority of ADA-positive patients, skin clearance (EASI scores) and adverse event rates were indistinguishable from ADA-negative patients. One rare case of serum sickness was noted in a patient with high-titer ADAs.

Discussion and Limitations

The study underscores that titer is the "master variable" in biologics immunogenicity. The higher incidence in adolescents may be due to transient IgM responses that do not transition to persistent IgG.

Limitations include the low number of high-titer cases, which restricts deep statistical sub-analysis, and the "snapshot" nature of periodic sampling. While OLE studies provided up to three years of data, the lifelong nature of AD necessitates continued long-term surveillance through real-world registries to monitor immunogenicity over decades.

Summary updated

Abstract

ClinicalTrials.gov, identifiers (NCT02277743, NCT02277769, NCT02260986, NCT02395133, NCT01949311, NCT03054428, NCT03345914, NCT02612454, and NCT03346434).
BibTeX
@inproceedings{kamal2024immunogenicity,
  author = {Mohamed Kamal and Matthew P. Kosloski and Ching‐Ha Lai and Michael A. Partridge and Manoj Rajadhyaksha and Vanaja Kanamaluru and Ashish Bansal and Arsalan Shabbir and Brad Shumel and Marius Ardeleanu and Susan Richards and Hong Yan and Christine Xu and Ainara Rodríguez-Marco and Jing Xiao and Faisal A. Khokhar and Guy Gherardi and Elisa Babilonia and Jennifer Maloney and Eric Mortensen and Bolanle Akinlade and Ned Braunstein and Neil Stahl and Albert Torri and John D. Davis and A. Thomas DiCioccio},
  title = {{Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1466372},
}
Figure